比较18F-FDG PET/CT标准预测伊匹木单抗与PD-1抑制剂治疗的转移性黑色素瘤患者治疗反应及临床结局
这项回顾性研究纳入57例转移性黑色素瘤患者,分别接受伊匹木单抗(25例)或PD-1抑制剂(32例)治疗,于治疗前及12至18周后行18F-FDG PET/CT,比较RECIST 1.1、EORTC、PERCIMT及MTV/TLG百分比变化等标准预测6个月临床获益的准确性。伊匹木单抗组MTV联合PERCIMT准确性最高(0.96),PD-1抑制剂组EORTC、MTV与TLG结果重叠(准确性0.97),上述参数在无进展生存分析中亦得到验证。
要点
- 伊匹木单抗组中MTV联合PERCIMT标准预测治疗反应准确性最高(0.96)。
- PD-1抑制剂组中EORTC、MTV与TLG预测准确性重叠(0.97)。
- 治疗开始后3至4个月行18F-FDG PET/CT可预测长期临床结局。
核心结论
- 免疫治疗开始后3至4个月行18F-FDG PET/CT可正确评估治疗反应,并能预测长期临床结局。
- 18F-FDG PET/CT的反应评估标准表现受治疗药物类别影响。
研究设计与样本
- 回顾性研究纳入57例转移性黑色素瘤患者,接受伊匹木单抗者25例(第1组),接受PD-1抑制剂者32例(第2组)。
- 所有患者于治疗前(PET0)及12至18周后(PET1)行18F-FDG PET/CT。
主要发现
- 第1组中预测治疗反应最佳者为MTV联合PERCIMT标准(准确性0.96)。
- 第2组中EORTC、MTV与TLG结果重叠(准确性0.97)。
- 上述参数在无进展生存分析中的可靠性亦得到确认。
关键数值与推荐
- PET1反应评估采用RECIST 1.1、EORTC、PERCIMT标准及最多5个靶病灶的MTV与TLG百分比变化。
- 以免疫治疗开始后6个月临床获益评估各标准在PET1的预测表现,并与无进展生存相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: : Immunotherapy currently represents one of the most effective therapies in metastatic melanoma. However, its indirect antineoplastic activity through the immune system has raised relevant challenges for diagnostic imaging in the evaluation of the response to treatment. PURPOSE: The aim of this retrospective study was to compare the diagnostic accuracy of different F-FDG PET/CT criteria to predict therapy response and clinical outcome in melanoma patients treated with immune checkpoint inhibitors. PATIENTS AND METHODS: Fifty-seven patients with metastatic melanoma treated with ipilimumab (n = 25; group 1) or with PD-1 inhibitors (n = 32; group 2) who performed an F-FDG PET/CT scan before treatment (PET0) and 12 to 18 weeks later (PET1) were retrospectively evaluated. Response at PET1 was evaluated according to RECIST 1.1, EORTC, PERCIMT (PET Response Evaluation Criteria for Immunotherapy), and by percentage change of metabolic tumor volume (MTV) and total lesion glycolysis of up to 5 target lesions. Performance of each criterion at PET1 to predict clinical benefit at 6 months since starting immunotherapy was assessed and correlated to progression-free survival. RESULTS: In group 1, the best predictor of therapy response was MTV combined with PERCIMT criteria (accuracy, 0.96). In group 2, overlapping results were found for EORTC, MTV, and total lesion glycolysis (accuracy, 0.97). The reliability of the above parameters was also confirmed in the progression-free survival analysis. CONCLUSIONS: F-FDG PET/CT performed after 3 to 4 months since starting immunotherapy can correctly evaluate response to treatment and can also able to predict long-term clinical outcome. Performance of F-FDG PET/CT and criteria for response assessment is influenced by the class of treatment.
引用
- Annovazzi A, Vari S, Giannarelli D, et al. Comparison of 18F-FDG PET/CT Criteria for the Prediction of Therapy Response and Clinical Outcome in Patients With Metastatic Melanoma Treated With Ipilimumab and PD-1 Inhibitors. Clin Nucl Med. 2020. PMID: 31977479. doi:10.1097/RLU.0000000000002921
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。